Abbreviations14,15-dihydroxy eicosatrienoic acid (14,15-DiHET); 1-aminobenzotriazole (ABT); 1-benzylimidazole (1BI); 20hydroxyeicosatetraenoic acid (20-HETE); 3-((4-(1H-imidazol-1-yl)benzamido)methyl)benzoic acid (inhibitor 9); 8-[(1H-benzotriazol-1-yl)amino]octanoic acid (8-BOA); arachidonic acid (AA); competing endogenous RNA (ceRNA); cytochrome P450 (CYP); cytochrome P450 reductase (CPR); epidermal growth factor (EGF); epoxyeicosatrienoic acid (EET); estrogen receptor alpha (ERα); ethyl (E)-4-(4-(N'hydroxyformimidamido)phenyl)butanoate (7c); fibroblast growth factor (FGF); gas chromatography-mass spectrometry (GC-MS); lauric acid (LA); liquid chromatography with tandem mass spectrometry (LC-MS/MS); luciferin-4F12 (Luc-4F12); luciferin-benzyl ether (Luc-BE); mechanism-based inactivator (MBI); mitogenactivated protein kinase (MAPK); myristic acid (MA); N-hydroxy-N'-(-butyl-2-methylphenyl)-formamidine (HET0016); nickel nitrilotriacetic (Ni-NTA); phosphoinositide 3-kinase/protein kinase B (PI3K/Akt); plateletderived growth factor (PDGF); polyunsaturated fatty acid (PUFA); soluble epoxide hydrolase (sEH); timedependent inhibition (TDI); triple negative negative breast cancer (TNBC); vascular endothelial growth factor (VEGF)
Pages and Word Count